within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX17_SacituzumabGovitecan;

model SacituzumabGovitecan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.888888888888889e-08,
    adminDuration = 600,
    adminMass = 10000 / 1000000,
    adminCount = 1,
    Vd = 0.00329,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00276,
    k12 = 8.88888888888889e-08,
    k21 = 8.88888888888889e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>SacituzumabGovitecan</td></tr><tr><td>ATC code:</td><td>L01FX17</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.29</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.14</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sacituzumab govitecan is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting Trop-2, linked to the cytotoxic agent SN-38, an active metabolite of irinotecan. It is used for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. It is FDA and EMA approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of sacituzumab govitecan (the antibody-drug conjugate, not unconjugated SN-38) in patients with advanced solid tumors as reported in adult females and non-small cell lung cancer patients after intravenous administration.</p><h4>References</h4><ol><li><p>Sathe, AG, et al., &amp; Othman, AA (2024). Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. <i>Clinical pharmacokinetics</i> 63(5) 669–681. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01366-3\">10.1007/s40262-024-01366-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38578394/\">https://pubmed.ncbi.nlm.nih.gov/38578394</a></p></li><li><p>Bardia, A, et al., &amp; Ocean, AJ (2021). Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 32(6) 746–756. DOI:<a href=\"https://doi.org/10.1016/j.annonc.2021.03.005\">10.1016/j.annonc.2021.03.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33741442/\">https://pubmed.ncbi.nlm.nih.gov/33741442</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01FX17 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end SacituzumabGovitecan;
